Compare Stocks → Better than Bitcoin? The Biotech Stock with 46,751% Potential (From Behind the Markets) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison CVE:IGXTSE:MBXCVE:MPHNASDAQ:NEPTNASDAQ:OKYO Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeIGXIntelGenx TechnologiesC$0.58+1.8%C$0.58C$0.17▼C$0.85C$87.32MN/A56,279 shs11,848 shsMBXMicrobix BiosystemsC$0.33-5.8%C$0.38C$0.23▼C$0.47C$44.38M0.2871,155 shs166,766 shsMPHMedicureC$1.00-2.0%C$1.13C$0.99▼C$1.80C$10.25M1.014,487 shs4,900 shsNEPTNeptune Wellness Solutions$0.39$0.19▼$28.00$906K2.19462,687 shs2.25 million shsOKYOOKYO Pharma$1.47+1.4%$1.45$0.92▼$3.25$42.38M0.04151,948 shs11,767 shs7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed InvestorsAs the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceIGXIntelGenx Technologies0.00%0.00%0.00%0.00%0.00%MBXMicrobix Biosystems0.00%-5.63%-12.99%-16.25%-12.99%MPHMedicure-6.42%-0.97%-15.00%-12.07%-22.14%NEPTNeptune Wellness Solutions0.00%0.00%0.00%-55.36%-99.22%OKYOOKYO Pharma+2.84%-1.36%+0.69%-8.81%+14.17%Better than Bitcoin? The Biotech Stock with 46,751% Potential (Ad)4x Better than Bitcoin Bitcoin would have to go from $68,000 to $314,000 to match the 463% gains we saw with Immunogen in December.Get the name of the stock here >>>MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationIGXIntelGenx TechnologiesN/AN/AN/AN/AN/AN/AN/AN/AMBXMicrobix BiosystemsN/AN/AN/AN/AN/AN/AN/AN/AMPHMedicureN/AN/AN/AN/AN/AN/AN/AN/ANEPTNeptune Wellness SolutionsN/AN/AN/AN/AN/AN/AN/AN/AOKYOOKYO Pharma3.141 of 5 stars3.55.00.00.02.81.70.6Analyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceIGXIntelGenx TechnologiesN/AN/AN/AN/AMBXMicrobix Biosystems3.00BuyN/AN/AMPHMedicureN/AN/AN/AN/ANEPTNeptune Wellness SolutionsN/AN/AN/AN/AOKYOOKYO Pharma3.00Buy$7.00376.16% UpsideCurrent Analyst RatingsLatest MPH, NEPT, MBX, IGX, and OKYO Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/22/2024OKYOOKYO PharmaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$6.00 ➝ $7.00(Data available from 4/26/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookIGXIntelGenx TechnologiesC$1.75M49.95C$0.08 per share7.16C$0.05 per share12.89MBXMicrobix BiosystemsC$22.42M1.98C$0.08 per share4.13C$0.20 per share1.63MPHMedicureC$22.94M0.45C$0.40 per share2.49C$2.10 per share0.48NEPTNeptune Wellness Solutions$52.62M0.00N/AN/A($91.90) per share0.00OKYOOKYO PharmaN/AN/AN/AN/A($0.08) per shareN/AProfitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateIGXIntelGenx TechnologiesN/A-C$0.08N/A∞N/AN/AN/AN/AN/AMBXMicrobix BiosystemsC$3.72MC$0.0310.83∞N/A16.57%14.66%1.87%5/9/2024 (Estimated)MPHMedicureC$1.08MC$0.0911.11∞N/A4.71%5.04%2.49%5/24/2024 (Estimated)NEPTNeptune Wellness Solutions-$60.46M-$106.72N/AN/AN/A-128.13%N/A-141.94%7/15/2024 (Estimated)OKYOOKYO Pharma-$13.27MN/A0.00N/AN/AN/AN/AN/A8/20/2024 (Estimated)Latest MPH, NEPT, MBX, IGX, and OKYO EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails4/8/2024Q4 2023MPHMedicureN/A-C$0.14-C$0.14-C$0.14N/AC$5.07 million2/14/2024Q1 2024MBXMicrobix BiosystemsN/AC$0.02+C$0.02C$0.02C$8.10 millionC$8.41 millionDividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthIGXIntelGenx TechnologiesN/AN/AN/AN/AN/AMBXMicrobix BiosystemsN/AN/AN/AN/AN/AMPHMedicureN/AN/AN/AN/AN/ANEPTNeptune Wellness SolutionsN/AN/AN/AN/AN/AOKYOOKYO PharmaN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioIGXIntelGenx Technologies164.622.772.69MBXMicrobix Biosystems24.538.535.57MPHMedicure2.862.281.29NEPTNeptune Wellness SolutionsN/A0.230.10OKYOOKYO PharmaN/AN/AN/AOwnershipInstitutional OwnershipCompanyInstitutional OwnershipIGXIntelGenx TechnologiesN/AMBXMicrobix Biosystems0.42%MPHMedicure23.10%NEPTNeptune Wellness Solutions14.44%OKYOOKYO Pharma2.97%Insider OwnershipCompanyInsider OwnershipIGXIntelGenx TechnologiesN/AMBXMicrobix Biosystems14.07%MPHMedicure26.99%NEPTNeptune Wellness Solutions5.10%OKYOOKYO Pharma40.46%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableIGXIntelGenx Technologies48150.55 millionN/ANot OptionableMBXMicrobix BiosystemsN/A136.55 millionN/ANot OptionableMPHMedicureN/A10.25 millionN/ANot OptionableNEPTNeptune Wellness Solutions584.53 million4.30 millionNot OptionableOKYOOKYO Pharma828.83 million17.17 millionNot OptionableMPH, NEPT, MBX, IGX, and OKYO HeadlinesSourceHeadlineOKYO Pharma to include additional analyses in upcoming dry eye disease Key Opinion Leader eventproactiveinvestors.com - April 9 at 8:39 AMOKYO Pharma to Reschedule Key Opinion Leader Event in Dry Eye Disease to May 2024globenewswire.com - April 8 at 7:00 PMOKYO Pharma Announces Upcoming Presentation of OK-101 Phase 2 Data for Dry Eye Disease at Eyecelerator 2024, a Partner Meeting of the American Society for Cataract and Refractive Surgeryglobenewswire.com - April 2 at 7:00 AMJapan authorities inspect second Kobayashi Pharma factory after deathsmsn.com - March 31 at 9:46 PMJapan dietary supplement maker probes five deathsmsn.com - March 29 at 8:56 AMAnalysts Offer Insights on Healthcare Companies: Kiora Pharmaceuticals (KPRX) and Genmab (GMAB)markets.businessinsider.com - March 27 at 6:32 PMOKYO Pharma gains after positive results from Phase 2 dry eye disease trialmsn.com - March 22 at 3:14 PMRelief For Dry Eye Disease? OKYO Pharma's Candidate Shows Durable Pain Relief In Mid-Stage Studymsn.com - March 22 at 3:14 PMOKYO Pharma says OK-101 shows statistically significant improvements for dry eye symptomsproactiveinvestors.com - March 22 at 8:52 AMOKYO Pharma Announces OK-101 Successfully Achieved Statistical Significance for Multiple Signs and Symptoms of Dry Eye Disease including Ocular Pain Relief in its First-in-Human Phase 2 Trial of OK-101globenewswire.com - March 22 at 7:00 AMOKYO Pharma to host event featuring Phase 2 trial results for OK-101 in dry eye diseaseproactiveinvestors.com - March 21 at 9:23 AMOKYO Pharma to Host Key Opinion Leader Event to Discuss New and Comprehensive Data from Phase 2 Dry Eye Disease Trialglobenewswire.com - March 21 at 7:00 AMOKYO Pharma to release Phase 2 dry eye disease trial results on Fridayproactiveinvestors.com - March 20 at 8:55 AMOKYO Pharma to Release New and Comprehensive Data from Phase 2 Dry Eye Disease Trial and Host Key Opinion Leader Eventglobenewswire.com - March 20 at 7:00 AMOKYO Pharma Limited (OKYO) Stock Price, News, Quote & History - Yahoo Financefinance.yahoo.com - March 19 at 11:17 AMTokyo stocks open lower as gains locked in, BOJ outcome awaitedmsn.com - March 19 at 1:09 AMOKYO Pharma (OKYO) Price Target Increased by 20.00% to 6.12msn.com - February 25 at 8:55 AMTokyo stocks open flat as gains locked in, exporters risemsn.com - February 20 at 1:07 PMOKYO Pharma shares surge on FDA clearance of Phase 2 neuropathic corneal pain trialproactiveinvestors.com - February 9 at 8:47 AMOKYO Pharma Receives FDA Approval of IND for OK-101 in Neuropathic Corneal Painfinance.yahoo.com - February 9 at 8:00 AMPulling plug on Aduhelm in AD, Biogen turns resources to Leqembibioworld.com - February 2 at 1:16 PMStock market today: Asian shares mostly rise after Wall Street rebounds led by tech stocksmsn.com - February 2 at 1:16 PMOKYO Pharma Announces Distinguished Ophthalmologists with Expertise in the Medical and Surgical Treatment of Ocular Surface Diseases Join its Scientific Advisory Boardfinance.yahoo.com - January 31 at 8:20 AMEagles files lawsuit in patent dispute over cancer therapymsn.com - January 18 at 9:32 AMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsIntelGenx TechnologiesCVE:IGXIntelGenx Technologies Corp., a drug delivery company, focuses on the development and manufacturing of novel oral thin film products for the pharmaceutical market. It offers INT0008/2008, a Rizatriptan oral film product for the treatment of migraine. The company's products under development comprise INT0004/2006, an antidepressant; INT0046/2018 for adult use; INT0007/2006 for the treatment of erectile dysfunction; INT0010/2006 for the treatment of neuropathic pain and nausea in cancer patients; INT0027/2011 to treat opioid addition; INT0036/2013 for schizophrenia; and INT0043/2015 to treat Alzheimer's disease; and INT0048/2020 for animal health. It is also developing INT0039/2013, INT0040/2014, INT0052/2020, and INT0053/2020. The company has licensing, development, and supply agreement with Tilray, Inc. and Gensco Pharma; and development agreement with Cynapsus Therapeutics Inc. IntelGenx Technologies Corp. was founded in 2003 and is headquartered in Montreal, Canada.Microbix BiosystemsTSE:MBXMicrobix Biosystems Inc., a life science company, develops and commercializes proprietary biological and technological solutions for human health and wellbeing in North America, Europe, and internationally. The company manufactures diagnostic-test products, such as test-controls under the QAPs brand; viral transport medium for collection of patient samples to test for pathogens including virus causing the COVID-19 disease under the DxTM brand; Kinlytic, a biologic thrombolytic drug used to treat blood clots; and antigen products. Microbix Biosystems Inc. was founded in 1988 and is headquartered in Mississauga, Canada.MedicureCVE:MPHMedicure Inc., a biopharmaceutical company, engages in the research, development, and commercialization of human therapies for the cardiovascular market. The company markets and distributes AGGRASTAT injection, a glycoprotein GP IIb/IIIa receptor antagonist for the treatment of acute coronary syndrome, including unstable angina and non-Q-wave myocardial infarction. It also offers ZYPITAMAG to treat patients with primary hyperlipidemia or mixed dyslipidemia. In addition, the company offers Sodium Nitroprusside injection for the reduction of blood pressure for adult and pediatric patients in hypertensive crisis, as well as for producing controlled hypotension to reduce bleeding during surgery, and for the treatment of acute congestive heart failure. It offers products through retail and mail order pharmacies. The company was incorporated in 1997 and is headquartered in Winnipeg, Canada.Neptune Wellness SolutionsNASDAQ:NEPTNeptune Wellness Solutions Inc., a health and wellness products company, specializes in the extraction, purification and formulation of cannabis products, as well as other specialty ingredients, such as MaxSimil, a patented ingredient that enhances the absorption of lipid-based nutraceuticals, and various other marine and seed oils. Its custom formulations are available in various delivery forms, such as softgels, liquid solutions, nutritional emulsions, and chewables. Neptune Wellness Solutions Inc. was founded in 1998 and is headquartered in Laval, Canada. OKYO PharmaNASDAQ:OKYOOKYO Pharma Limited, a clinical-stage biopharmaceutical company, engages in developing therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead preclinical product candidate is OK-101, which is in Phase II clinical trials for the treatment of dry eye disease. The company is also developing OK-201, a bovine adrenal medulla, lipidated-peptide preclinical analogue candidate for the treatment of neuropathic chronic pain. The company was incorporated in 2007 and is headquartered in London, the United Kingdom. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.